BIOLINERX LTD/S (NASDAQ:BLRX) was the recipient of a significant drop in short interest during the month of February. As of February 28th, there was short interest totalling 714,355 shares, a drop of 38.1% from the February 15th total of 1,154,627 shares. Approximately 0.5% of the shares of the stock are sold short. Based on an average daily volume of 1,256,708 shares, the days-to-cover ratio is currently 0.6 days.
BLRX stock opened at $0.42 on Friday. The firm has a market cap of $45.04 million, a price-to-earnings ratio of -1.56 and a beta of 1.70. BIOLINERX LTD/S has a 52-week low of $0.38 and a 52-week high of $1.84.
Hedge funds have recently bought and sold shares of the business. Two Sigma Securities LLC acquired a new stake in BIOLINERX LTD/S during the fourth quarter worth $25,000. Menta Capital LLC acquired a new stake in BIOLINERX LTD/S during the fourth quarter worth $33,000. ETF Managers Group LLC increased its stake in BIOLINERX LTD/S by 79.4% during the fourth quarter. ETF Managers Group LLC now owns 375,909 shares of the biotechnology company’s stock worth $164,000 after acquiring an additional 166,386 shares during the last quarter. Finally, Fosun International Ltd acquired a new stake in BIOLINERX LTD/S during the third quarter worth $1,412,000. 33.79% of the stock is owned by institutional investors.
BLRX has been the subject of several recent research reports. Oppenheimer set a $3.00 price target on BIOLINERX LTD/S and gave the company a “buy” rating in a report on Wednesday, December 12th. HC Wainwright set a $4.00 price target on BIOLINERX LTD/S and gave the company a “buy” rating in a report on Tuesday, December 11th. Finally, Maxim Group set a $2.00 price target on BIOLINERX LTD/S and gave the company a “buy” rating in a report on Wednesday, December 12th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $2.50.
ILLEGAL ACTIVITY WARNING: This story was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this story can be viewed at https://www.americanbankingnews.com/2019/03/15/short-interest-in-biolinerx-ltd-s-blrx-drops-by-38-1.html.
About BIOLINERX LTD/S
BioLineRx Ltd., a clinical stage biopharmaceutical development company focused on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions.
Read More: The risks of owning bonds
Receive News & Ratings for BIOLINERX LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLINERX LTD/S and related companies with MarketBeat.com's FREE daily email newsletter.